Agalimmune: Agalimmune Receives £1.2 Million ($2 million) Milestone Payment
Agalimmune Ltd, a biopharmaceutical company focused on the development of innovative immunotherapeutics for the treatment of cancer, announced today that it has received a milestone payment from Loxbridge Research LLP…Click to Continue »
Read full article »
Agalimmune focuses on developing an anti-cancer immunotherapy technology for the treatment of patients with solid tumors.
Read more